Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Tuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values < 7 µM, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery.
Guilherme Felipe
GF
Dos Santos Fernandes
Daniela Hartmann
DH
Jornada
Paula Carolina
PC
de Souza
Chung Man
CM
Chin
Fernando Rogerio
FR
Pavan
School of Pharmaceutical Sciences, State University of Sao Paulo, Zipcode: 14801- 902, Araraquara, Brazil. santosjl@fcfar.unesp.br.
Jean Leandro
JL
Dos Santos
D000818:Animals; D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology*; D055808:Drug Discovery; D006801:Humans; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000378:metabolism; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents